Recent advancements in HIV research are bringing us closer to a “functional cure.” At the Conference on Retroviruses and Opportunistic Infections (CROI) 2025, Gilead Sciences presented groundbreaking data from its innovative HIV treatment portfolio. The new findings highlight a transformative portfolio and a rapidly advancing pipeline focused on expanding choices and enhancing outcomes for those with HIV, while continuing to reach towards a cure.
One of the key highlights is the investigational long-acting, twice-yearly treatment regimen of Lenacapavir and broadly neutralizing antibodies (bNAbs), which met its primary endpoint in a Phase 2 study and gained Breakthrough Therapy Designation. Additionally, the late-breaker oral presentation of Phase 2 results from the first HIV cure clinical trial conducted in South Africa showcased promising outcomes.
Scientists at Rockefeller University are also exploring innovative treatments, and individuals like Logan Bellew are participating in clinical trials to help pave the way. Logan’s journey, documented through photographs and medical records, offers a unique perspective on living with HIV and the quest for a cure. Drs. Marina Caskey and Michel Nussenzweig of the SNF Institute have discovered and characterized broadly neutralizing monoclonal antibodies, which are a promising step toward a potential HIV cure. Their work is detailed in a news story published by iMEdD in December 2024.
